NCT03901573 2025-10-22
High-Risk Skin Cancers With Atezolizumab Plus NT-I7
NeoImmuneTech
Phase 1/2 Terminated
NeoImmuneTech
European Organisation for Research and Treatment of Cancer - EORTC
Washington University School of Medicine
University of California, Davis
University Hospital Tuebingen
Celldex Therapeutics